Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium Tuberculosis-infected Individuals

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2009 Jan 20

PMID 19151191

Citations 63

Authors

Clare R Sander

Ansar A Pathan

Natalie E R Beveridge

Ian Poulton

Angela Minassian

Nicola Alder

Johan van Wijgerden

Adrian V S Hill

Fergus V Gleeson

Robert J O Davies

Geoffrey Pasvol

Helen McShane

Affiliations

Soon will be listed here.

Abstract

Rationale: An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care.

Objectives: To evaluate the safety and immunogenicity of a leading new TB vaccine, recombinant Modified Vaccinia Ankara expressing Antigen 85A (MVA85A) in individuals with LTBI.

Methods: An open-label, phase I trial of MVA85A was performed in 12 subjects with LTBI recruited from TB contact clinics in Oxford and London or by poster advertisements in Oxford hospitals. Patients were assessed clinically and had blood samples drawn for immunological analysis over a 52-week period after vaccination with MVA85A. Thoracic computed tomography scans were performed at baseline and at 10 weeks after vaccination. Safety of MVA85A was assessed by clinical, radiological, and inflammatory markers. The immunogenicity of MVA85A was assessed by IFNgamma and IL-2 ELISpot assays and FACS.

Measurements And Main Results: MVA85A was safe in subjects with LTBI, with comparable adverse events to previous trials of MVA85A. There were no clinically significant changes in inflammatory markers or thoracic computed tomography scans after vaccination. MVA85A induced a strong antigen-specific IFN-gamma and IL-2 response that was durable for 52 weeks. The magnitude of IFN-gamma response was comparable to previous trials of MVA85A in bacillus Calmette-Guérin-vaccinated individuals. Antigen 85A-specific polyfunctional CD4(+) T cells were detectable prior to vaccination with statistically significant increases in cell numbers after vaccination.

Conclusions: MVA85A is safe and highly immunogenic in individuals with LTBI. These results will facilitate further trials in TB-endemic areas. Clinical trial registered with www.clinicaltrials.gov (NCT00456183).

Citing Articles

Preclinical Evaluation of TB/FLU-04L-An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis.

Shurygina A, Zabolotnykh N, Vinogradova T, Khairullin B, Kassenov M, Nurpeisova A Int J Mol Sci. 2023; 24(8).

PMID: 37108602 PMC: 10138401. DOI: 10.3390/ijms24087439.

Therapeutic Vaccines for Tuberculosis: An Overview.

Bouzeyen R, Javid B Front Immunol. 2022; 13:878471.

PMID: 35812462 PMC: 9263712. DOI: 10.3389/fimmu.2022.878471.

An Update on Tuberculosis Vaccines.

Gopalaswamy R, Subbian S Methods Mol Biol. 2021; 2410:387-409.

PMID: 34914059 DOI: 10.1007/978-1-0716-1884-4_20.

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy -Infected Adults.

Riste M, Marshall J, Satti I, Harris S, Wilkie M, Ramon R Vaccines (Basel). 2021; 9(4).

PMID: 33923628 PMC: 8073411. DOI: 10.3390/vaccines9040396.

The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01 and MVA85A.

Ullah I, Bibi S, Haq I, Safia , Ullah K, Ge L Front Immunol. 2020; 11:1806.

PMID: 33133057 PMC: 7578575. DOI: 10.3389/fimmu.2020.01806.

References

Diederich S, Thomas M, Semik M, Lenzen H, Roos N, Weber A . Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur Radiol. 2004; 14(4):691-702. DOI: 10.1007/s00330-003-2200-5. View

Cappelli G, Volpe P, Sanduzzi A, Sacchi A, Colizzi V, Mariani F . Human macrophage gamma interferon decreases gene expression but not replication of Mycobacterium tuberculosis: analysis of the host-pathogen reciprocal influence on transcription in a comparison of strains H37Rv and CMT97. Infect Immun. 2001; 69(12):7262-70. PMC: 98810. DOI: 10.1128/IAI.69.12.7262-7270.2001. View

Sone S, Takashima S, Li F, Yang Z, Honda T, Maruyama Y . Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998; 351(9111):1242-5. DOI: 10.1016/S0140-6736(97)08229-9. View

Joshi R, Patil S, Kalantri S, Schwartzman K, Menzies D, Pai M . Prevalence of abnormal radiological findings in health care workers with latent tuberculosis infection and correlations with T cell immune response. PLoS One. 2007; 2(8):e805. PMC: 1950085. DOI: 10.1371/journal.pone.0000805. View

Pai M, Joshi R, Bandyopadhyay M, Narang P, Dogra S, Taksande B . Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection. 2007; 35(2):98-103. PMC: 2951985. DOI: 10.1007/s15010-007-6114-z. View

Newport M, Huxley C, Huston S, Hawrylowicz C, Oostra B, Williamson R . A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996; 335(26):1941-9. DOI: 10.1056/NEJM199612263352602. View

Romano M, DSouza S, Adnet P, Laali R, Jurion F, Palfliet K . Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine. 2006; 24(16):3353-64. DOI: 10.1016/j.vaccine.2005.12.066. View

Nawa T, Nakagawa T, Kusano S, Kawasaki Y, Sugawara Y, Nakata H . Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies. Chest. 2002; 122(1):15-20. DOI: 10.1378/chest.122.1.15. View

Ewer K, Millington K, Deeks J, Alvarez L, Bryant G, Lalvani A . Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006; 174(7):831-9. DOI: 10.1164/rccm.200511-1783OC. View

10.

Betts M, Nason M, West S, De Rosa S, Migueles S, Abraham J . HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107(12):4781-9. PMC: 1895811. DOI: 10.1182/blood-2005-12-4818. View

11.

Zhang Y . The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005; 45:529-64. DOI: 10.1146/annurev.pharmtox.45.120403.100120. View

12.

Beveridge N, Price D, Casazza J, Pathan A, Sander C, Asher T . Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol. 2007; 37(11):3089-100. PMC: 2365909. DOI: 10.1002/eji.200737504. View

13.

Diederich S, Hansen J, Wormanns D . Resolving small pulmonary nodules: CT features. Eur Radiol. 2005; 15(10):2064-9. DOI: 10.1007/s00330-005-2836-4. View

14.

Perfetto S, Chattopadhyay P, Lamoreaux L, Nguyen R, Ambrozak D, Koup R . Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods. 2006; 313(1-2):199-208. DOI: 10.1016/j.jim.2006.04.007. View

15.

Wilkinson K, Kon O, Newton S, Meintjes G, Davidson R, Pasvol G . Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis. 2006; 193(3):354-9. DOI: 10.1086/499311. View

16.

Fischbach F, Knollmann F, Griesshaber V, Freund T, Akkol E, Felix R . Detection of pulmonary nodules by multislice computed tomography: improved detection rate with reduced slice thickness. Eur Radiol. 2003; 13(10):2378-83. DOI: 10.1007/s00330-003-1915-7. View

17.

Warren R, Victor T, Streicher E, Richardson M, Beyers N, Gey van Pittius N . Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med. 2004; 169(5):610-4. DOI: 10.1164/rccm.200305-714OC. View

18.

Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, NARUKE T, Suemasu K . Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology. 1996; 201(3):798-802. DOI: 10.1148/radiology.201.3.8939234. View

19.

Sodhi A, Gong J, Silva C, Qian D, Barnes P . Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis. 1997; 25(3):617-20. DOI: 10.1086/513769. View

20.

Shi L, Jung Y, Tyagi S, Gennaro M, North R . Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci U S A. 2002; 100(1):241-6. PMC: 140939. DOI: 10.1073/pnas.0136863100. View